Health Care • Biotechnology: Laboratory Analytical Instruments
$157.00 ▼ -8.78
(-5.30%)
MKT CAP: $17.52B • VOL: 3.18M
52W L $81 52W H $169
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$132
MEDIAN
$176
MEAN
$179
HIGH
$214
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE RVTY TAPE
RVTY // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $189.97 | $180.55 | 2025-02-14 | $142.87 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $197.82 | $185.26 | 2025-02-06 | $147.58 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $178.98 | $172.70 | 2025-01-29 | $150.72 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $160.14 | — | 2025-01-17 | $153.86 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $138.16 | $149.15 | 2025-01-09 | $139.73 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $186.83 | $163.28 | 2024-12-18 | $136.59 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $152.29 | $158.57 | 2024-12-04 | $146.01 | -4.3% | 48% | C |